ResearcherThe Catholic University of Korea St. Vincent's HospitalNo recent work listed

H.S. Park

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111189740. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 paper

Papers 1

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicent… Co-author DOI 10.1016/j.esmoop.2021.100049 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jung Hun Kang · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Choong‐kun Lee · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Hye Jin Choi · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Woo Kyun Bae · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Sung Hee Lim · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Joon Oh Park · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗
Changhoon Yoo · 1 shared paper, 2021 · strength 0.10
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.